Morris, Lynn.Chen, Xi.Alam, Shabnam Munir.Tomaras, Georgia D.Zhang, Ruijun.Marshall, Dawn J.Chen, Bing.Parks, Robert J.Foulger, Andrew.Jaeger, Frederick H.Donathan, Michele.Bilska, Mira.Gray, Elin Solomonovna.Abdool Karim, Salim Safurdeen.Kepler, Thomas B.Whitesides, John.Montefiori, David Charles.Moody, Michael Anthony.Liao, Hua-Xin.Haynes, Barton F.2012-11-202012-11-2020112011Morris, L. et al. 2011. Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B Ccell sorting. PLoS ONE 6 (9), pp. 1-10.1932-6203http://dx.doi.org/10.1371/journal.pone.0023532http://hdl.handle.net/10413/7905Broadly neutralizing antibodies are not commonly produced in HIV-1 infected individuals nor by experimental HIV-1 vaccines. When these antibodies do occur, it is important to be able to isolate and characterize them to provide clues for vaccine design. CAP206 is a South African subtype C HIV-1-infected individual previously shown to have broadly neutralizing plasma antibodies targeting the envelope gp41 distal membrane proximal external region (MPER). We have now used a fluoresceinated peptide tetramer antigen with specific cell sorting to isolate a human neutralizing monoclonal antibody (mAb) against the HIV-1 envelope gp41 MPER. The isolated recombinant mAb, CAP206-CH12, utilized a portion of the distal MPER (HXB2 amino acid residues, 673–680) and neutralized a subset of HIV-1 pseudoviruses sensitive to CAP206 plasma antibodies. Interestingly, this mAb was polyreactive and used the same germ-line variable heavy (VH1-69) and variable kappa light chain (VK3-20) gene families as the prototype broadly neutralizing anti-MPER mAb, 4E10 (residues 672–680). These data indicate that there are multiple immunogenic targets in the C-terminus of the MPER of HIV-1 gp41 envelope and suggests that gp41 neutralizing epitopes may interact with a restricted set of naive B cells during HIV-1 infection.enHIV antibodies.HIV infections--Prevention and control.Peer reviewed journal article